Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7189808 | 0.89 | KDM4E (0.37) | PTPN1KDM4EXDHS1PR1 | |
| SCHEMBL7665158 | 0.87 | KDM4E (0.36) | PTPN1KDM4E | |
| SCHEMBL7189802 | 0.87 | KDM4E (0.39) | PTPN1KDM4EXDHTHRATHRB | |
| SCHEMBL7597545 | 0.83 | PTPN1 (0.55) | PTPN1KDM4EXDHTHRATHRB | |
| SCHEMBL7190925 | 0.81 | PTPN1 (0.35) | PTPN1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL7597539 | 0.79 | PTPN1 (0.35) | PTPN1 | |
| SCHEMBL7189804 | 0.78 | PTPN5 (0.43) | PTPN1 | |
| SCHEMBL7665155 | 0.77 | PTPN5 (0.44) | PTPN1 | |
| SCHEMBL7198006 | 0.75 | PTPN1 (0.42) | PTPN1KDM4E | |
| SCHEMBL7595285 | 0.73 | PTPN1 (0.35) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTPN1 13/4885KDM4E 2275/4885XDH 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.